Global Inhalation Anesthesia Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Global Inhalation Anesthesia Market Research Report 2023-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2029

Inhalation anesthesia refers to the anesthetic medications that are induced for maintaining the levels of general anesthesia and sedation in the body during surgery. Some of the commonly used inhalation anesthetics include desflurane, isoflurane, and sevoflurane. These anesthetics are administered using a laryngeal face airway and a tracheal tube connected to a vaporizer. They are highly effective in small doses and can induce respiratory depression, reduce arterial blood pressure and increase cerebral blood flow when used in unmoderated quantities. In comparison to the traditionally used intravenous variants, inhalation anesthesia does not accumulate in the body and aids in preventing excessive dosage, while promoting the normal functioning of the patient.

Market Overview:

The latest research study on the global Inhalation Anesthesia market finds that the global Inhalation Anesthesia market reached a value of USD 1733.38 million in 2022. It’s expected that the market will achieve USD 2502.31 million by 2028, exhibiting a CAGR of 6.31% during the forecast period.

Influence of COVID-19 Outbreak on Inhalation Anesthesia Industry Development

The distribution channel segment is divided into offline and online, the offline segment is dominating the market currently, and due to emergence of COVID-19, the online market witnessed a significant growth in 2020. The COVID-19 Outbreak has led to a decline in offline passenger flow, and the advantages of e-commerce companies have become prominent. During the epidemic prevention and control period, some inhalation anesthesia enterprises did not carry out internet marketing and promotion for their business, so they encountered great resistance in undertaking business. For enterprises that fail to make good use of network promotion means, there is almost no market development during the epidemic period, and the original offline market development plan is disrupted, and the epidemic will face fierce market homogenization competition, which is expected to have a great impact on the company's business throughout the year.

The epidemic will have a short-term impact on inhalation anesthesia industry, but it is relatively limited. Due to the impact of the epidemic, the production of raw materials and equipment procurement and transportation supply are difficult to be in place, and upstream enterprises affect the work schedule of downstream enterprises. Equipment manufacturing and product manufacturing enterprises in inhalation anesthesia industry are affected to different degrees, and the production and delivery work may be delayed to some extent. Meanwhile, if it fails to meet the customer's delivery time requirements according to the contract, it may lead to the customer looking for another enterprise and lose business.

The impact of COVID-19 on the inhalation anesthesia industry will involve all major links and all entities in the industry chain. The company's management efficiency has declined, commuting has been severely hindered, production plans have been severely hindered, network expansion has been delayed, marketing has been delayed, brand adjustments have been forced, market sales have declined, and company and employee revenue have declined. The government has also put forward higher requirements for the production and operation of enterprises. Although various industries around the world are gradually resuming work, production and demand will not pick up rapidly and substantially, and will require a certain recovery period.

Market Drivers

Increased use of these in various disease diagnosis drive the inhalation anesthesia market growth. The rapid rise in the aging population suffering from cancer, cardiovascular, spinal, orthopedic, respiratory, gastrointestinal, neurological, and other diseases and disorders is anticipated to drive the growth. The increasing prevalence of chronic medical disorders requiring surgical treatments is one of the key factors driving the growth of the market. Moreover, the rising geriatric population, which is more susceptible to ailments, such as cardiovascular, neurological, respiratory and degenerative disorders, is providing a thrust to the market growth. The increasing number of orthopedic procedures such as ligament and other soft tissue repair procedures is also contributing to the growth of the daycare ambulatory surgeries, which is expected to boost usage of inhalation anesthesia. Hospitals and other ambulatory healthcare centers are widely using sevoflurane and other ether-based inhalation anesthetic agents with low pungency and non-irritant odor for patients with asthma or sensitive air passages. Furthermore, an increasing number of emergency cases and accidents is also expected to positively influence market growth over the forecast period.

Region Overview:

United States had the highest growth rate of all regions.

Company Overview:

Baxter is one of the major players operating in the Inhalation Anesthesia market, holding a share of 43.55% in 2022.

Baxter International Inc. is an American multinational health care company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat kidney disease, and other chronic and acute medical conditions. Baxter's BioScience business produces recombinant and blood plasma proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies and other chronic and acute blood-related conditions; products for regenerative medicine, and vaccines. Baxter's Medical Products business produces intravenous products and other products used in the delivery of fluids and drugs to patients; inhalational anaesthetics; contract manufacturing services; and products to treat end-stage kidney disease, or irreversible kidney failure, including products for peritoneal dialysis and hemodialysis.

AbbVie is an American publicly traded biopharmaceutical company founded in 2013. It originated as a spin-off of Abbott Laboratories. On October 19, 2011, Abbott Laboratories announced its plan to separate into two publicly traded companies. The new Abbott Laboratories would specialize in diversified products including medical devices, diagnostic equipment and nutrition products, while AbbVie would operate as a research-based pharmaceutical manufacturer. The separation was effective January 1, 2013, and AbbVie was officially listed on the New York Stock Exchange (ABBV) on January 2, 2013.

Segmentation Overview:

Among different product types, Sevoflurane segment is anticipated to contribute the largest market share in 2027.

Application Overview:

By application, the Maintenance segment occupied the biggest share from 2017 to 2022.

Key Companies in the global Inhalation Anesthesia market covered in Chapter 3:

Piramal Enterprises Limited
AbbVie Inc.
Maruishi
Lunan Pharmaceutical Group Co.Ltd.
Halocarbon Products Corporation
Baxter
Jiangsu Hengrui Medicine Co. Ltd.

In Chapter 4 and Chapter 14.2, on the basis of types, the Inhalation Anesthesia market from 2018 to 2029 is primarily split into:

Sevoflurane
Isoflurane
Desflurane

In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Inhalation Anesthesia market from 2018 to 2029 covers:

Induction
Maintenance

Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2018-2029) of the following regions are covered in Chapter 8 to Chapter 14:

North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)